Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018)
Eton Pharmaceuticals (ETON) posted Preferred Stock Liabilities of $21.2 million for Q3 2018, up 11.35% sequentially from $19.0 million in Q4 2017.
Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Eton Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $21.2 million in Q3 2018.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $21.2 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $21.2 million (changed N/A YoY) and the FY2017 annual result came in at $19.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $21.2 million in Q3 2018 per ETON's latest filing, from $19.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $21.2 million in Q3 2018 and troughed at $19.0 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 21.16 Mn |
| Dec 31, 2017 | 19.00 Mn |